Show notes
Mahmoud Zureik discusses risk of bleeding in patients with non-valvular atrial fibrillation who switched and those who remained on a vitamin K antagonist.
Mahmoud Zureik discusses risk of bleeding in patients with non-valvular atrial fibrillation who switched and those who remained on a vitamin K antagonist.